As of 8:30:48 AM GMT+1. Market Open.
Breakdown
TTM
5/31/2024
5/31/2023
5/31/2022
5/31/2021
Total Revenue
--
--
--
266.0000
--
Cost of Revenue
--
--
20,633.0000
73,543.0000
--
Gross Profit
--
--
-20,633.0000
-73,277.0000
--
Operating Expense
-8,991.0000
18,058.0000
19,943.0000
72,127.0000
89,520.0000
Operating Income
8,991.0000
-18,058.0000
-40,576.0000
-145,404.0000
-89,520.0000
Net Non Operating Interest Income Expense
-15,652.0000
-18,173.0000
-30,498.0000
-61,563.0000
-61,241.0000
Other Income Expense
-12,382.0000
-13,610.0000
-8,750.0000
-3,853.0000
-25,704.0000
Pretax Income
-19,043.0000
-49,841.0000
-79,824.0000
-210,820.0000
-176,465.0000
Net Income Common Stockholders
-20,525.0000
-51,324.0000
-86,736.0000
-212,448.0000
-178,152.0000
Diluted NI Available to Com Stockholders
-20,525.0000
-51,324.0000
-86,736.0000
-212,448.0000
-178,152.0000
Basic EPS
-0.02
-0.05
-0.10
-0.31
-0.30
Diluted EPS
-0.02
-0.05
-0.10
-0.31
-0.30
Basic Average Shares
1,022,373.0000
969,509.0000
836,528.0000
676,900.0000
587,590.0000
Diluted Average Shares
1,038,184.0000
969,509.0000
836,528.0000
676,900.0000
587,590.0000
Total Operating Income as Reported
8,991.0000
-18,058.0000
-40,576.0000
-145,404.0000
-104,596.0000
Total Expenses
-8,991.0000
18,058.0000
40,576.0000
145,670.0000
89,520.0000
Net Income from Continuing & Discontinued Operation
-19,043.0000
-49,841.0000
-79,824.0000
-210,820.0000
-176,465.0000
Normalized Income
-6,661.0000
-36,231.0000
-71,074.0000
-206,967.0000
-150,761.0000
Interest Income
--
--
--
--
2.0000
Interest Expense
5,428.0000
5,735.0000
6,750.0000
15,066.0000
61,031.0000
Net Interest Income
-15,652.0000
-18,173.0000
-30,498.0000
-61,563.0000
-61,241.0000
EBIT
-13,615.0000
-44,106.0000
-73,074.0000
-195,754.0000
-115,434.0000
EBITDA
-13,591.0000
-44,077.0000
-72,899.0000
-194,973.0000
-113,637.0000
Reconciled Cost of Revenue
--
--
20,633.0000
73,543.0000
--
Reconciled Depreciation
24.0000
29.0000
175.0000
781.0000
1,797.0000
Net Income from Continuing Operation Net Minority Interest
-19,043.0000
-49,841.0000
-79,824.0000
-210,820.0000
-176,465.0000
Total Unusual Items Excluding Goodwill
-12,382.0000
-13,610.0000
-8,750.0000
-3,853.0000
-25,704.0000
Total Unusual Items
-12,382.0000
-13,610.0000
-8,750.0000
-3,853.0000
-25,704.0000
Normalized EBITDA
-1,209.0000
-30,467.0000
-64,149.0000
-191,120.0000
-87,933.0000
5/31/2021 - 8/28/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
8GN.F Cessatech A/S
1.5800
-2.17%
CELUW Celularity Inc.
0.0141
-3.42%
J90.F NurExone Biologic Inc.
0.5200
-3.70%
VLA.VI Valneva SE
1.7510
-5.30%
BBZA.DE BB Biotech AG Ord
38.25
-0.13%
FRX.TO Fennec Pharmaceuticals Inc.
8.68
0.00%
TGRP TRON Group Inc.
0.0420
-13.40%
NRSNW NeuroSense Therapeutics Ltd.
0.3000
+20.00%
FYB.DE Formycon AG
53.50
+1.33%
CLVLY Clinuvel Pharmaceuticals Limited
7.91
+1.02%